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Oral contraception users do not have an increased overall lifetime cancer risk; 
reductions in colorectal, endometrial and ovarian cancer persist at least 30 years.  
 
Short title 




Background: Oral contraceptives have been used by hundreds of millions of women 
around the world. Important questions remain regarding the very long-term cancer 
risks associated with oral contraception. Despite previous research important 
questions remain about the safety of these contraceptives: i) how long do endometrial, 
ovarian and colorectal cancer benefits persist for? ii) does combined oral 
contraceptive use during the reproductive years produce new cancer risks later in life? 
and iii) what is the overall balance of cancer among past users as they enter the later 
stages of their lives? 
Objectives: To examine the very long-term cancer risks or benefits associated with 
use of combined oral contraceptives, including the estimated overall life-time balance.  
Study design: 46,022 women recruited to the UK Royal College of General 
Practitioners’ Oral Contraception Study during 1968/69 were followed-up for up to 44 
years. Directly standardised rates of specific and any cancer were calculated for ever 
and never users of combined oral contraceptives; standardised for age, parity, social 
class and smoking. Attributable risk percentage and preventive fraction percentage 
were calculated. Poisson regression adjusting for the same variables was used to 
estimate incidence rate ratios (IRR) between ever and never users, and examine 
effects by time since last oral contraceptive use  
Results: There were 4661 ever users with at least one cancer during 884,895 woman-
years of observation and 2341 never users with at least one cancer during 388,505 
woman-years of observation.  Ever use of oral contraceptives was associated with 
reduced colorectal (IRR 0·81, 99% confidence interval, CI 0·66 to 0·99), endometrial 
(IRR 0·66, 99% CI 0·48 to 0·89), ovarian (IRR 0·67, 99% CI 0·50 to 0·89) and 
lymphatic and haematopoietic cancer (IRR 0·74, 99% CI 0·58 to 0·94). An increased 
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risk of lung cancer was seen only among ever users who smoked at recruitment.  An 
increased risk of breast and cervical cancer seen in current and recent users appeared 
to be lost within about five years of stopping oral contraception, with no evidence of 
either cancer recurring at increased risk in ever users with time.  There was no 
evidence of new cancer risks appearing later in life among women who had used oral 
contraceptives. Thus, the overall balance of cancer risk among past users of oral 
contraceptives was neutral with the increased risks counterbalanced by the 
endometrial, ovarian and colorectal cancer benefits that persist at least 30 years.  
Conclusions: Most women who choose to use oral contraceptives do not expose 
themselves to long-term cancer harms; instead many benefit from important 
reductions in some cancers which persist for many years after stopping. 
 







Since its introduction, first in the United States in 19601, combined oral 
contraceptives have been used by hundreds of millions of women around the world. 
Today, it is estimated that 100-150 million women use this contraceptive method on a 
daily basis2.   Concerns were expressed early on about the method’s carcinogenic 
potential1.  Cancer was of particular concern given the likely high level of usage and 
the 11-22% lifetime cancer risk among women living in different parts of the world3.
  
These concerns, and frequent media scares, have left many women wondering 
whether they have exposed themsleves to long-term harm by using this method of 
contraception.  
 
There have been many, mostly case-control, studies looking at combined oral 
contraception and different types of cancer.  Collectively the evidence suggests that 
current and recent users of combined oral contraceptives have an increased risk of 
breast and cervical cancer, and that long-term users in regions at low risk of hepatitis 
B virus may have an increased risk of liver cancer4. Conversely, users of combined 
oral contraceptives appear to have a reduced risk of endometrial and ovarian cancer, 
an effect which appears to persist for many years after stopping. Current users of 
combined oral contraceptives also appear to be protected from colorectal cancer, with 
uncertainty about the length of protection after stopping.   
 
Even with this extensive body of evidence important questions remain: i) how long do 
the endometrial, ovarian and colorectal cancer benefits persist for? ii) does combined 
oral contraceptive use during the reproductive years produce new cancer risks that 
emerge later in life? and iii) what is the overall balance of cancer among past users of 
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combined oral contraceptives as they enter the later stages of their lives?  These 
questions are best answered by large-scale, population-based studies with the 
prospective collection of exposure information and very long-term follow-up.  We 
report here results from 44 years follow-up of the Royal College of General 
Practitioners’ Oral Contraception Study, the longest running study of the health 
effects of oral contraception in the world.   
 
Materials and Methods 
Between May 1968 and July 1969, 1400 general practitioners (GPs) throughout the 
UK recruited approximately 23,000 women who were using oral contraceptives and 
23,000 women who had never used this method of contraception.5 All women were 
married or co-habiting, most were Caucasian and their mean age at recruitment was 
29 years. Information collected at recruitment included previous use of oral 
contraception,  smoking habits, social class (based on partner’s occupation using the 
Registrar General’s 1966 Classification of Occupations6), parity and significant past 
medical history. Women remained under GP follow-up until: (i) they were no longer 
registered with the recruiting doctor (usually because the woman moved away - 
approximately 56% of total cohort); (ii) their doctor left the study (13%); (iii) they 
obtained contraceptives from another source (3%); (iv) they died (2%); or (v) GP 
follow-up stopped in December 1996 (26%).  Whilst under GP follow-up, GPs 
provided on a six-monthly report form information about any hormonal preparations 
prescribed, any pregnancies, new episodes of illness or surgery, and cause of death.  
All GP supplied information was coded by a team of trained clerks, with queries 




In the mid 1970’s, approximately three quarters of the cohort was ‘flagged’ at 
National Health Service (NHS) central registries in Scotland and England. This 
enabled subsequent cancers and deaths occurring among flagged women to be 
reported to the study anonymously, including after women left GP follow-up.  The 
other quarter could not be flagged because the women had already left the study when 
flagging occurred.  
 
 We used the GP supplied data to determine each woman’s pill status, and her 
contribution to the analysis. Most women in the study (91%) who used oral 
contraceptives did so before age 38 years.  Ever users were women recruited as takers 
and subsequently prescribed oral contraception (nearly always a combined oestrogen 
and progestogen preparation).  For each calendar month that a woman used an oral 
contraceptive, one month was added to the period of observation (denominator) of 
ever users, as were periods after stopping. Women recruited as never users who were 
subsequently prescribed an oral contraceptive were included in the ever user group 
from the month of prescription.  Never users lost to GP follow-up before 1996 and 
aged <38 years when lost contributed data (as never users) up to the point of their loss 
before being censored- because of uncertainty about whether they subsequently used 
oral contraceptives. Never users lost to GP follow-up before 1996 and aged ≥38 years 
when lost were likely to remain never users and so continued to make a contribution 
to the never user group if flagged (otherwise they were censored at this point). Never 
users who were still in the study when GP follow-up stopped in 1996 were deemed 
unlikely to change pill status, and so remained in the analysis. For a small number of 
ever users (2,690/28,983: 9.3%) we did not have a stop date notified by the GP.  For 
these women we assumed oral contraceptive usage stopped one year after the last 
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recorded prescription. The effect of this assumption is to slightly underestimate time 
since stopping if a woman used oral contraception for less than 12 months after the 
last recorded prescription, and overestimate it if used for a longer period.  
 
The analysis included cancers and periods of observation up to: (a) the date of first 
relevant cancer or date left study for i) all non-flagged women, and ii) flagged never 
users lost from the study before 1996 and aged <38 years when lost; (b) date of 
relevant cancer or 31st December 2012 for: i) all flagged women still under GP 
observation at December 1996 ii) flagged never users lost before 1996 and aged ≥38 
years when lost, and iii) flagged ever users lost from the study before 1996 (Figure 1).  
Most cancers were notified through flagging by the central registries (i.e. 5467/7002 
(78%) of all cancers).   
 
The cancers were coded using the International Classification of Diseases, 8th revision 
(ICD-8)7 grouped into (a) individual categories: oesophagus and stomach (code 150-
151), colon and rectum (153-154), gallbladder and liver (155-156), pancreas (157), 
lung (162), skin-melanoma (172), skin-other (173), breast (174), invasive cervix 
(180), endometrium (182), ovary (183), bladder and kidney (188-189), central 
nervous system and pituitary (191 and 1943), thyroid (193), site unknown (199), 
lymphatic and haematopoietic (200-208), other cancers (any code between 140-209 
not already mentioned); (b) any cancer (140-209). If a discrepancy in event type or 
date occurred between GP and registry notification, clarification was sought from the 
GP whenever possible. If this was not possible the GP supplied information was used, 




Direct standardisation was used to estimate the rates of cancer amongst ever and never 
users. The standardisation variables using the total study population were age (<30, 
30-39, 40-49, 50-59, 60-69, 70+) and parity (0, 1, 2, 3+) at time of event, and smoking 
(0, 1-14, 15+ cigarettes daily) and social class (non-manual: social classes I-IIIa and 
students,  manual: social classes IIIb-V and armed forces) at recruitment. Poisson 
regression was used to estimate the incidence rate ratio (IRR) and its 99% confidence 
interval (CI) for ever versus never users for each of the cancer types, adjusted for the 
same categories of age, parity, smoking and social class as above.  The exception was 
when we stratified the data by a particular variable (e.g. smoking habits at 
recruitment), when we adjusted the IRRs for the other three variables.  We calculated 
99% CIs to allow for the large number of comparisons, indicating statistical 
significance at the 1% level. 
 
We excluded women known to have the cancer before recruitment, and events and 
periods of observation related to pregnancy. Only first events in each cancer category 
were included; subsequent periods of observation were removed from the 
denominator of analyses relating to the same cancer but included in analyses of other 
cancers (since the women remained at risk of having another type of cancer). The 
analysis of any cancer risk only included the first cancer, with subsequent observation 
censored.  In all analyses, women were censored at death. By end of follow-up 7248 
deaths occurred; 3003 deaths in never and 4245 deaths in ever users of oral 
contraception.    
 
Attributable risk (AR) was calculated by subtracting cancer incidence in never users 
from that in ever users. When the IRR was <1 the preventive fraction percent (PF%) 
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was estimated, i.e. the percentage of cancer reduction in ever users that might be 
prevented by combined oral contraception. When the IRR was >1 the AR% was 
calculated, i.e. the percentage of cancers in ever users that might be attributable to 
combined oral contraception. 
 
For our time since last use analysis, we divided the ever users into current and less 
than 5 years since use, 5-<15 years since use, 15-<25 years since use, 25-<35 years 
and 35 years and more since last use. We undertook adjusted Poisson regression as 
above to estimate the IRR in each category relative to never users. Due to the strong 
relationship between age and time since last use of oral contraception, we did not 
undertake standardisation to obtain adjusted rates. 
 
The study was established before the introduction of research ethics committees in the 
UK. Even so, procedures were used to maintain the confidentiality of women i.e. 
correspondence between participating doctors and the study, and between the NHS 




The dataset contained 4661 ever users with at least one cancer during 884,895 
woman-years of observation and 2341 never users with at least one cancer during  
388,505 woman-years of observation; a 81% increase in cancers and 18% increase in 
periods of observation since our previous cancer analysis8. Approximately a tenth of 
never users who experienced cancer (246 women: 10.5%) and a similar proportion of 
ever users (458 women: 9.8%) had more than one type of cancer. The mean age of 
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women at December 2012 was 70.2 (standard deviation (SD) 8.0) years and median 
cohort follow-up 40.7 years (inter-quartile range 6.1, 44.6).  At recruitment oral 
contraceptive users were slightly younger and more likely to smoke or be of non-
manual class than never users, but of similar parity (Table 1). The mean duration of 
pill use was 3.66 (SD 3.5) years. 
  
Compared to never users, ever users of oral contraception had a statistically non-
significant 4% reduced risk of any cancer (Table 2: IRR 0.96, 99% CI 0.90 to 1.03). 
The IRR for the most common cancer, breast cancer, was close to unity (IRR 1.04, 
99% CI 0.91 to 1.17). There were reductions among ever users, compared with never 
users, in colorectal (IRR 0.81, 99% CI 0.66 to 0.99), endometrial (IRR 0.66, 99% CI 
0.48 to 0.89), ovarian (IRR 0.67, 99% CI 0.50 to 0.89), and lymphatic and 
haematopoietic cancer (IRR 0.74, 0.58 to 0.94).  An increased risk of lung cancer 
among all ever users was not statistically significant at the 1% level. When never and 
ever users were stratified by smoking habits at recruitment (Table 3), the IRR for lung 
cancer among non-smoking ever users was 0.73 (99% CI 0.42 to 1.26) and that among 
smoking ever users 1.34 (99% CI 1.06 to 1.69).  
 
In general, the IRRs resulted in modest ARs (Table 2), indicating a low absolute risk 
(or benefit) of any specific cancer. The PF%s suggest (assuming that the associated 
IRRs represent a true causal relationship) that perhaps a third of endometrial and 
ovarian cancers, and nearly a fifth of colorectal cancers, occurring in ever users might 




In both contraceptive groups, the incidence of any cancer increased with age and 
smoking, and was higher in the manual social class group (Table 4).  Most of the 
IRRs in the age, smoking, social class and parity subgroups were below unity, 
although none reached statistical significance.  
 
Table 5 shows the IRRs by time since since last use. Statistically significant increased 
IRRs were observed among current and recent (<5 years since stopping) users for 
breast, cervcial and any cancer, associations which largely disappeared by 5-<15 years 
after stopping.  There was no evidence of important cancer risks appearing many 
years after stopping oral contraception; indeed the IRRs for several cancer types 
(colorectal, breast, ovarian, CNS and pituitary, lympathic and haematopoietic, other, 
site unknown, and any) were significantly reduced 35 or more years after stopping.   
 
Comment 
Our results suggest that users of oral contraceptives are protected from colorectal, 
endometrial and ovarian cancer for many years after stopping, perhaps for more than 
35 years for colorectal and ovarian cancer.  An increased breast and cervical cancer 
risk seen in current and recent users appears to be lost within about 5 years of 
stopping oral contraception, with no evidence of either cancer recurring at increased 
risk in ever users with time.  An increased risk of lung cancer was seen only in ever 
users who were smokers at recruitment.  There was no evidence of new cancer risks 
appearing later in life among women who had used oral contraceptives.  These results 
provide strong evidence that most women do not expose themselves to long-term 





The large number of women recruited, and very prolonged  follow-up, resulted in 
nearly 1.3 million women-years of observation.  The near doubling of events since our 
last report enabled us to provide separate risk estimates for oesophagus and stomach, 
pancreas, non-melanoma skin, bladder and kidney, thyroid, and lymphatic and 
haematopoietic cancer (previously included in the ‘other cancer’ category8), and more 
precise risk estimates for other cancers. Although some inaccuracies in cancer 
notifications from the registries may have occurred, systematic differences between 
contraceptive groups are unlikely.  
 
The study has been prone to large losses to follow-up.  Previous analyses have shown 
that women lost to GP follow-up in the study had similar mortality to those still under 
observation,9 suggesting no systematic bias from loss to follow-up. Mortality rates in 
the study have been found to be lower than the general population,10 mainly because 
women with chronic disease were not recruited.5  Age-specific rates of all cancer seen 
in our study, however, were generally only slightly lower than those for women living 
in the UK for 2011-1311 (Table 6)  The observed differences would affect our 
estimates of absolute risk but not comparisons between contraceptive groups unless 
oral contraception impacts differently upon those with underlying health conditions or 
risk factors for cancer. We found little evidence of this with regards to age, parity, 
social class or smoking (Table 4). It is possible however that at least some of the 
lower incidence rate ratios for some types of cancer seen in the more than 35 years 
after stopping group may have been due to a healthy cohort effect. 
 
The incidence rate ratios were adjusted for smoking and social class at recruitment, 
and age and parity at time of event. Residual confounding from other personal or 
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lifestyle factors might have affected our results. For example, we did not have 
information for the whole cohort about potential confounders such as body mass 
index, alcohol, diet, exercise, menarche, menopause or family history.  Neither did we 
have updated smoking information for all the women.   In a separate sub-study we 
found that more women stopped smoking than started, but with fewer pill users 
stopping than never users.12   In theory this means that a larger proportion of women in 
the smoking group at recruitment will have been misclassified as smokers when in 
fact they became ex-smokers during the study than those in the non-smoker group at 
recruitment who subsequently started smoking. This differential misclassification 
could have led to an underestimation of effects of smoking in smoking-related 
cancers. This said, in a sub-group of the cohort who provided updated information 
about smoking habits in a health survey in the mid-1990s, risk estimates of 
myocardial infarction were virtually identical when derived using updated smoking 
information compared to those produced using smoking information at recruitment.12   
 
In this paper we could not adjust for hormone replacement therapy (HRT) use since 
we did not know about such use after women left GP observation although we did 
collect information about such usage whilst under GP follow-up. Oral contraceptive 
users in our study who did not have a hysterectomy were more likely to subsequently 
use HRT than similar never users13. In a previous paper in which we examined cancer 
risk among women whilst under GP observation, adjustment for HRT made little 
difference to the unadjusted results8.  HRT use, however, is associated with an 
increased risk of breast and ovarian cancer in current and recent users14,15.  It is 
noteworthy, therefore, that we found no overall increased risk of breast cancer among 
oral contraceptive ever users, even though many will have also used HRT.  Similarly 
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noteworthy is the continued observation of a significant reduction overall in ovarian 
cancer risk among ever users of oral contraception, suggesting a powerful 
counterbalance to any harmful ovarian effects of subsequent HRT use.  
 
We censored women from analyses of the same cancer but not from analyses of other 
cancers because women remained at risk of developing another type of cancer.  It is 
possible that treatments for a first cancer may affect the risk of another cancer.  For 
example, tamoxifen treatment for breast cancer may increase the risk of endometrial 
cancer.16 Overall 704 (10.0%) of all women with one cancer had at least another type 
of cancer, suggesting minimal problems from such concerns. 
 
We did not conduct analyses by the hormonal content of the pill, principally because 
most women in the study used more than one preparation, making it impossible to 
know whether any cancer associations are due to the effects of the last preparation 
used or lingering effects from previously used products. Most oral contraceptives used 
in our study contained 50µg of oestrogen combined with an older progestogen, used 
mostly by women who had completed their families. Our findings, therefore, may not 
reflect the experience of today’s user, although limited evidence suggests similar 
effects from currently available products.17-23  Very few studies have reported cancer 
associations with non-oral combined hormonal contraception. Limited evidence 
related to deep venous thrombosis suggests that such preparations have a similar, or 
slightly higher, risk than oral products.24 Thus, until empirical evidence becomes 
available, users of non-oral combined hormonal contraceptives should assume that 





Few studies have assessed the very long term cancer risk among women who have 
used oral contraceptives. Meta-analyses of breast cancer and oral contraception show 
a modest elevated risk among ever users25, 26, reflecting the temporary increased risk 
in current and recent users. The absence of long-term breast cancer risk in our study is 
reassuring, supporting findings from two other cohort studies: the Oxford-Family 
Planning Association (FPA) study27 and the Nurses’ Health Study.28  The Oxford-
FPA study found an elevated risk of cervical cancer among ever users of oral 
contraceptives.27 This observation was contrary to our findings, and a re-analysis of 
global data which suggests that the elevated cervical cancer risk in current and recent 
users disappears within about 10 years of stopping oral contraception.29   The reduced 
risk of ovarian and endometrial cancer in our study is consistent with the global 
evidence that oral contraception provides prolonged protection.20,21 Colorectal cancer 
was also reduced in ever users in our study, including those more than 35 years after 
stopping.   
 
Widespread implementation of effective cervical cancer prevention measures such as 
HPV vaccination or cervical cancer screening should result in reduced cervical cancer 
incidence over time; resulting in an even more favourable overall balance of main 
gynaecological cancer in ever users. 
 
The IARC Working Group concluded that oral contraception is unlikely to alter the 
risk of thyroid, lung, stomach, urinary tract, gallbladder, pancreas cancer, or the risk 
of lymphoma, cutaneous melanoma and tumours of the central nervous system4. Our 





In many part of the world, such as the Americas, Europe and Western Pacific, lung 
cancer is common or becoming so3.  Most lung cancers occur in people who have 
smoked or been exposed to smoking. In our study, the AR of smoking ≥ 15 cigarettes 
a day at recruitment was approximately 250 per 100,000 woman-years; a powerful 
reminder of the need for strong policies to dissuade women from smoking.  
 
Patterns of cancer vary widely around the world3.  Our results therefore, may not 
reflect the experience of oral contractive users living in other global regions.  It is 
reassuring, however, to find in one of the regions of the world with high cancer 
incidence among women, no indication of substantial lifetime cancer risk among ever 
users, more than 35 years after stopping this popular method of contraception.  
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Table 1.  Characteristics of ever and never users or oral contraception at recruitment 









Age (years) n (%) n (%) n (%) 
<30 13701 (59.8) 13521 (58.5) 27222 (59.2) 
30 – 39  7553 (33.0)  7725 (33.4) 15278 (33.2) 
40 + 1666  (7.2) 1856  (8.1) 3522 (7.6) 
    
Mean age at recruitment (SD)* 28.5 (6.7) 29.0 (6.5) 28.8 (6.6) 
    
Number cigarettes smoked     
0 11904 (51.9)  13569 (58.7) 25473 (55.4) 
1 – 14  6261 (27.3)  5900 (25.5) 12161 (26.4) 
15+  4755 (20.8)   3633 (15.7)   8388 (18.2) 
    
Parity     
0 3401 (14.8) 4881 (21.1)   8282 (18.0) 
1 4520 (19.7) 6476 (28.0) 10996 (23.9) 
2 7543 (32.9) 7157 (31.0) 14700 (31.9) 
3 7456 (32.5) 4588 (19.9) 12044 (26.2) 
    
Mean (SD) 2.1 (0.9) 2.0 (0.9) 2.1 (0.9) 
    
Social class     
Non-manual   8585 (37.5)   8417 (36.4) 17002 (36.9) 
Manual 14335 (62.5) 14685 (63.6) 29020 (63.1) 




Table 2. Risk of cancer among ever and never users of oral contraceptives in the RCGP Oral Contraception Study. 
 
  Standardised Rate† (n)     
Malignancies ICD-8* Ever Users Never Users IRR‡ (99% CI) AR§ AR%‖ PF%¶ 
Oesophagus & stomach 150-151 14·51 (129) 16·59 (73) 0.87 (0.59, 1.27) -2·08  12·5 
Colon & rectum 153-154 47·85 (418) 59·16 (270) 0.81 (0.66, 0.99) -11·31  19·1 
Liver & gallbladder 155-156 4·65 (41) 5·72 (25) 0.87 (0.45, 1.69) -1·07  18·7 
Pancreas 157 13·33 (114) 13·47 (61) 1.00 (0.66, 1.52) -0·14  1·0 
Lung 162 59·16 (553) 49·19 (205) 1.17 (0.95, 1.45) 9·97 16·8  
Skin: melanoma 172 19·76 (173) 18·34 (78) 1.12 (0.78, 1.60) 1·42 7·2  
Skin: other 173 103·04 (882) 93·73 (423) 1.11 (0.95, 1.29) 9·31 9·0  
Breast 174 159·94 (1422) 155·16 (649) 1.04 (0.91, 1.17) 4·78 3·0  
Invasive cervix 180 15·45 (147) 11·56 (45) 1.31 (0.84, 2.04) 3·89 25·2  
Endometrium 182 19·42 (168) 29·56 (127) 0.66 (0.48, 0.89) -10·14  34·3 
Ovary 183 22·10 (194) 33·27 (142) 0.67 (0.50, 0.89) -11·17  33·6 
Bladder & kidney 188-189 17·64 (159) 20·25 (88) 0.87 (0.61, 1.23) -2·61  12·9 
CNS & pituitary 191,1943 5·73 (51) 6·95 (32) 0.76 (0.42, 1.36) -1·22  17·5 
Thyroid 193 2·42 (22) 2·28 (10) 1.02 (0.37, 2.74) 0·14 5·8  
Site unknown 199 23·61 (212) 28·22 (122) 0.84 (0.63, 1.13) -4·61  16·3 
Lymphatic & haematopoietic 200-208 31·90 (281) 43·18 (189) 0.74 (0.58, 0.94) -11·28  26·1 
Other cancers  37·25 (336) 38·95 (166) 0.96 (0.75, 1.23) 1·49 4·1  
Main gynaecological 180,182,183 56·51 (503) 74·31 (312) 0.76 (0.63, 0.91) -17·80  24·0 
Any cancer 140-209 542·44 (4661) 566·09 (2341) 0.96 (0.90, 1.03) -23·65  4·2 
*ICD-8: International Classification of Diseases, version 8   
†Standardised rate per 100 000 woman-years, standardised for age, parity, smoking and social status 
‡ IRR incidence rate ratio and 99% confidence interval from Poisson regression adjusted for age, parity, smoking and social status 
§AR: Attributable risk per 100,000 woman-years; ‖AR%: Attributable risk percentage; ¶PF%: Preventive fraction percentage 
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Table 3. Risk of cancer among ever and never users of oral contraceptives in the 
RCGP Oral Contraception Study, stratified by smoking at recruitment. 
 
 
 Ever versus Never 
 
 Non-smokers Smokers 
Malignancies ICD-8* IRR† (99% CI) IRR† (99% CI) 
Oesophagus & stomach 150-151 0.74 (0.39, 1.39) 0.97 (0.59, 1.58) 
Colon & rectum 153-154 0.82 (0.62, 1.07) 0.79 (0.57, 1.08) 
Liver & gallbladder 155-156 1.05 (0.41, 2.74) 0.74 (0.29, 1.85) 
Pancreas 157 0.92 (0.53, 1.59) 1.14 (0.60, 2.16) 
Lung 162 0.73 (0.42, 1.26) 1.34 (1.06, 1.69) 
Skin: melanoma 172 1.16 (0.76, 1.78) 1.03 (0.54, 1.97) 
Skin: other 173 1.14 (0.93, 1.38) 1.06 (0.82, 1.36) 
Breast 174 1.00 (0.85, 1.18) 1.09 (0.90, 1.33) 
Invasive cervix 180 1.67 (0.82, 3.40) 1.12 (0.64, 1.96) 
Endometrium 182 0.76 (0.51, 1.13) 0.52 (0.32, 0.85) 
Ovary 183 0.67 (0.46, 0.97) 0.68 (0.43, 1.07) 
Bladder & kidney 188-189 1.06 (0.62, 1.80) 0.75 (0.48, 1.19) 
CNS & pituitary 1,911,943 0.72 (0.34, 1.52) 0.81 (0.31, 2.10) 
Thyroid 193 1.92 (0.36, 10.1) 0.65 (0.18, 2.37) 
Site unknown 199 0.94 (0.60, 1.51) 0.79 (0.53, 1.16) 
Lymphatic & 
haematopoietic 
200-208 0.69 (0.50, 0.95) 0.82 (0.56, 1.21) 
Other cancers  1.04 (0.73, 1.48) 0.90 (0.63, 1.27) 
Main gynaecological 180,182,183 0.80 (0.62, 1.03) 0.71 (0.53, 0.94) 
Any cancer 140-209 0.95 (0.87, 1.04) 0.99 (0.89, 1.09) 
*ICD-8: International Classification of Diseases, version 8 
†IRR incidence rate ratio and 99% confidence interval from Poisson regression 




Table 4. Risk of any cancer among ever and never users of different age, parity, 




Standardised Rate* (n)  
Ever users Never users IRR† (99% CI) 
Age (years) 
< 30 39·98 (25) 40·48 (12) 0.88 (0.35, 2.18) 
30-39 104·77 (188) 131·31 (92) 0.80 (0.57, 1.11) 
40-49 276·62 (585) 295·97 (260) 0.92 (0.76, 1.11) 
50-59 573·61 (1173) 633·75 (518) 0.91 (0.79, 1.04) 
60-69 1044·90 (1669) 1003·72 (707) 1.03 (0.92, 1.16) 
70 + 1720·88 (1021) 1795·54 (752) 0.95 (0.84, 1.08) 
Smoking (cigarettes daily) 
0 476·35 (2214) 505·55 (1323) 0.95 (0.87, 1.04) 
1-14 552·62 (1277) 565·46 (567) 0.98 (0.86, 1.12) 
15+ 732·67 (1170) 759·13 (451) 0.97 (0.84, 1.12) 
Social class 
Non-manual 531·99 (1680) 559·74 (882) 0.97 (0.89, 1.05) 
Manual 546·18 (2981) 569·10 (1459) 0.96 (0.86, 1.07) 
Parity 
0 515·81 (252) 604·56 (201) 0.88 (0.68, 1.14) 
1 556·75 (603) 488·38 (332) 1.14 (0.95, 1.36) 
2 545·16 (1772) 573·93 (898) 0.94 (0.84, 1.05) 
3+ 537·61 (2034) 578·79 (910) 0.93 (0.84, 1.03) 
*Standardised rate per 100 000 woman-years, standardised for age, parity, smoking, 
and social status, except where the variable itself is being examined. 
†IRR incidence rate ratio and 99% Confidence interval from Poisson regression 
adjusted for the other three variables stratified by variable under examination 
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Table 5.  Risk of cancer among ever users of oral contraceptives in the RCGP Oral Contraception Study by time since estimated last use. 
 
    
Never 
user 
Time since last oral contraceptive use (years) 
 Current and <5 5-15 15-25 25-35 35+ 
Malignancies n  n IRR* (99% CI) n IRR* (99% CI) n IRR* (99% CI) n IRR* (99% CI) n IRR* (99% CI) 
Oesophagus & stomach 73 5 1.06 (0.26, 4.29) 14 1.08 (0.46, 2.49) 28 0.93 (0.51, 1.71) 51 0.89 (0.55, 1.43) 31 0.74 (0.42, 1.29) 
Colon & rectum 270 14 0.87 (0.39, 1.96) 40 0.91 (0.56, 1.47) 103 1.00 (0.73, 1.37) 162 0.81 (0.63, 1.05) 99 0.67 (0.49, 0.91) 
Liver & gallbladder 25 1 1.28 (0.07, 22.4) 4 1.27 (0.26, 6.18) 10 1.21 (0.43, 3.44) 14 0.75 (0.31, 1.78) 12 0.78 (0.31, 1.94) 
Pancreas 61 3 2.33 (0.43, 12.6) 6 0.86 (0.26, 2.82) 28 1.34 (0.71, 2.51) 50 1.08 (0.66, 1.78) 27 0.74 (0.41, 1.35) 
Lung 205 12 1.15 (0.48, 2.74) 43 1.20 (0.74, 1.94) 116 1.22 (0.89, 1.67) 234 1.23 (0.96, 1.58) 148 1.07 (0.81, 1.42) 
Skin: melanoma 78 21 1.44 (0.67. 3.10) 23 0.90 (0.46, 1.75) 32 0.88 (0.50, 1.54) 66 1.37 (0.88, 2.14) 31 1.01 (0.57, 1.80) 
Skin: other 423 28 1.16 (0.65, 2.05) 83 1.17 (0.83, 1.66) 179 1.10 (0.86, 1.40) 349 1.13 (0.94, 1.37) 243 1.07 (0.87, 1.32) 
Breast 649 129 1.48 (1.10, 1.97) 238 1.12 (0.91, 1.39) 371 1.05 (0.88, 1.24) 491 1.10 (0.94, 1.28) 193 0.75 (0.60, 0.93) 
Invasive cervix 45 50 2.32 (1.24, 4.34) 42 1.52 (0.84, 2.75) 27 1.05 (0.55, 2.01) 22 0.98 (0.48, 1.99) 6 0.51 (0.16, 1.67) 
Endometrium 127 5 0.61 (0.17, 2.18) 13 0.44 (0.20, 0.97) 46 0.70 (0.44, 1.11) 56 0.58 (0.38, 0.88) 48 0.83 (0.53, 1.31) 
Ovary 142 8 0.49 (0.18, 1.36) 25 0.63 (0.35, 1.15) 51 0.71 (0.46, 1.10) 80 0.80 (0.55, 1.15) 30 0.50 (0.29, 0.84) 
Bladder & kidney 88 2 0.50 (0.07, 3.54) 18 1.34 (0.63, 2.83) 45 1.25 (0.75, 2.06) 56 0.77 (0.49, 1.20) 38 0.72 (0.43, 1.19) 
CNS & pituitary 32 5 2.20 (0.49, 9.99) 8 1.16 (0.37, 3.57) 13 0.84 (0.35, 2.04) 21 0.84 (0.41, 1.76) 4 0.25 (0.06, 0.99) 
Thyroid 10 2 1.45 (0.14, 14.8) 7 2.29 (0.52, 10.1) 4 0.79 (0.16, 3.86) 4 0.56 (0.12, 2.62) 5 1.10 (0.25, 4.83) 
Site unknown 122 6 1.53 (0.47, 5.00) 18 0.92 (0.45, 1.85) 50 0.93 (0.59, 1.46) 99 0.99 (0.70, 1.41) 39 0.56 (0.34, 0.90) 
Lymphatic & 
haematopoietic 
189 25 0.92 (0.47, 1.80) 28 0.63 (0.36, 0.12) 68 0.87 (0.60, 1.28) 108 0.81 (0.59, 1.11) 52 0.55 (0.36, 0.83) 
Other cancers 166 21 1.20 (0.59, 2.44) 43 1.07 (0.66, 1.75) 77 0.99 (0.68, 1.44) 140 1.11 (0.82, 1.49) 55 0.65 (0.43, 0.97) 
Main gynaecological 312 63 1.21 (0.79, 1.85) 79 0.78 (0.55, 1.11) 121 0.74 (0.56, 0.99) 157 0.73 (0.56, 0.94) 83 0.65 (0.47, 0.91) 
Any cancer 2341 328 1.28 (1.08, 1.54) 609 1.02 (0.90, 1.16) 1125 1.01 (0.91, 1.11) 1718 1.00 (0.92, 1.08) 881 0.78 (0.71, 0.87) 
 




Table 6.  Comparison of age-specific incidence rate of all cancer in 2011-2013 in the 
UK and the RCGP Oral Contraception Study, for women aged 30-75 years. 
 
*Source: Cancer Research UK.  Female age-specific incidence rates of all cancers 
excluding non-melanoma skin cancer (C00-97 Excl. C44): 2011-2013. 
http://www.cancerresearchuk.org/health-professional/cancer-
statistics/incidence/age#heading-Zero accessed 3.8.16. 
  





Incidence rate per 
100,000 women Number 
Incidence rate per 
100,000 women 
30-34 2239 105.2 106 94.9 
35-39 3239 159.0 174 127.2 
40-44 5833 252.7 301 202.5 
45-49 9617 406.1 544 362.1 
50-54 12188 570.3 706 480.5 
55-59 13552 726.1 985 701.5 
60-64 18577 997.3 1227 937.0 
65-69 21713 1278.6 1149 1159.6 









The figure shows the follow-up of the Royal College of General Practitioner’s Oral 
Contraception Study from recruitment in 1968-69 to December 2012 
